Heart specialists in Hull are playing a leading role in a major national research trial which could help shape the future treatment of patients undergoing heart valve surgery.
The Cardiac Surgery team at Castle Hill Hospital is one of the leading recruiting sites for the AFFECT trial, a National Institute for Health and Care Research-funded study involving more than 30 centres across the UK. The national study is being led by researchers at The James Cook University Hospital in Middlesbrough.
The trial is looking to answer an important question about which blood-thinning medication provides the safest and most effective treatment for patients who have undergone mitral valve repair surgery and also have a heart rhythm problem.
Benjamin Omoregbee, Locum Consultant Cardiac Surgeon at Castle Hill Hospital, is Principal Investigator for the trial in Hull, supported by research nurses and an Associate Principal Investigator.
Mr Omoregbee said: “We are one of the leading recruiting sites in the UK and it is fantastic for Hull patients to have the opportunity to take part in this important national research.
“The trial is trying to answer a fundamental question around anticoagulation and help establish which medication is best for patients going forward. By recruiting patients here in Hull, we are contributing to the evidence that could help guide future treatment.”
The study aims to recruit 1,282 adults undergoing mitral valve repair surgery across UK cardiothoracic centres. Participants are randomly allocated either a Direct Oral Anticoagulant (DOAC) or a vitamin K antagonist (VKA), such as warfarin.
Researchers will assess outcomes including stroke prevention, quality of life and cost-effectiveness. More than 130 patients have already joined the trial nationally and started treatment.
Professor Enoch Akowuah, chief investigator for the AFFECT trial, said: “The AFFECT Trial will provide high-quality evidence to guide national treatment decisions and improve long-term outcomes for patients across the UK and internationally.”
Eligible patients will be approached by their clinical teams about taking part. If you’re interested in taking part, you can also speak to your care team.